Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Treatment of Myotonia: Lamotrigine versus Namuscla
2021-003784-94Phase 3Terminated
- Sponsor
- Rigshospitalet
- Start
- Nov 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of fresolimumab and lamotrigine in myotonia congenita (MC), Thomsen disease (ADMC), paramyotonia congenita (PMC) and 2 more (2 arms), sponsored by Rigshospitalet. Primary endpoint: Myotonia Behavior Scale (MBS) score. Started Nov 2021; status: terminated.
02
Drugs
fresolimumablamotrigine
03
Conditions
myotonia congenita (MC)Thomsen disease (ADMC)paramyotonia congenita (PMC)hyperkalemic periodic paralysis (HyperKPP)non-dystrophic myotonia (NDM)
Beyond the preview
Go deeper on 2021-003784-94.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-003784-94.